Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness

Qurratul A. Warsi, Alison J. Huang, Rachel Hess, Lily A. Arya, Holly E. Richter, Catherine S. Bradley, Rebecca G. Rogers, Deborah L. Myers, Karen C. Johnson, William D. Winkelman, William (Tom) Gregory, Stephen R. Kraus, Michael Schembri, Jeanette S. Brown, Katie L. Stone, Leslee L. Subak

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the association between pharmacologic therapy for urgency urinary incontinence (UUI) and sleep quality. METHODS: We conducted a planned secondary data analysis of sleep outcomes in a previously conducted multicenter, double-blind, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence among community-dwelling women self-diagnosed using the 3-Incontinence Questions questionnaire. Participants (N=645) were assigned randomly to 4-8 mg antimuscarinic therapy daily or placebo. At baseline and 12 weeks, participants completed a validated voiding diary to evaluate incontinence and voiding symptoms, the Pittsburgh Sleep Quality Index to evaluate sleep quality, and the Epworth Sleepiness Scale to evaluate daytime sleepiness. RESULTS: Mean (SD) age was 56 (±14) years, 68% were white, and 57% had poor sleep quality (Pittsburgh Sleep Quality Index score greater than 5). Mean frequency of any urinary incontinence and UUI was 4.6 and 3.9 episodes/d, respectively. After 12 weeks, women randomized to the antimuscarinic group reported greater decrease compared with the placebo group in UUI frequency (0.9 episodes/d; P<.001) and diurnal and nocturnal voiding frequency (P<.05). As compared with the placebo group, women in the antimuscarinic group also reported greater improvement in sleep quality (total Pittsburgh Sleep Quality Index score 0.48; P=.02) with greater improvement in sleep duration and sleep efficiency subscales (P<.05). The intervention did not affect daytime sleepiness. CONCLUSION: Pharmacologic treatment of UUI is associated with decreased incontinence frequency and nocturia and improvement in overall sleep quality, sleep duration, and sleep efficiency. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00862745.

Original languageEnglish (US)
Pages (from-to)204-211
Number of pages8
JournalObstetrics and Gynecology
Volume131
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Urinary Incontinence
Sleep
Muscarinic Antagonists
Therapeutics
Placebos
Nocturia
Independent Living
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Warsi, Q. A., Huang, A. J., Hess, R., Arya, L. A., Richter, H. E., Bradley, C. S., ... Subak, L. L. (2018). Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. Obstetrics and Gynecology, 131(2), 204-211. https://doi.org/10.1097/AOG.0000000000002443

Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. / Warsi, Qurratul A.; Huang, Alison J.; Hess, Rachel; Arya, Lily A.; Richter, Holly E.; Bradley, Catherine S.; Rogers, Rebecca G.; Myers, Deborah L.; Johnson, Karen C.; Winkelman, William D.; Gregory, William (Tom); Kraus, Stephen R.; Schembri, Michael; Brown, Jeanette S.; Stone, Katie L.; Subak, Leslee L.

In: Obstetrics and Gynecology, Vol. 131, No. 2, 01.02.2018, p. 204-211.

Research output: Contribution to journalArticle

Warsi, QA, Huang, AJ, Hess, R, Arya, LA, Richter, HE, Bradley, CS, Rogers, RG, Myers, DL, Johnson, KC, Winkelman, WD, Gregory, WT, Kraus, SR, Schembri, M, Brown, JS, Stone, KL & Subak, LL 2018, 'Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness', Obstetrics and Gynecology, vol. 131, no. 2, pp. 204-211. https://doi.org/10.1097/AOG.0000000000002443
Warsi, Qurratul A. ; Huang, Alison J. ; Hess, Rachel ; Arya, Lily A. ; Richter, Holly E. ; Bradley, Catherine S. ; Rogers, Rebecca G. ; Myers, Deborah L. ; Johnson, Karen C. ; Winkelman, William D. ; Gregory, William (Tom) ; Kraus, Stephen R. ; Schembri, Michael ; Brown, Jeanette S. ; Stone, Katie L. ; Subak, Leslee L. / Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness. In: Obstetrics and Gynecology. 2018 ; Vol. 131, No. 2. pp. 204-211.
@article{17206267b393428ab985dc89a3c178c9,
title = "Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness",
abstract = "OBJECTIVE: To evaluate the association between pharmacologic therapy for urgency urinary incontinence (UUI) and sleep quality. METHODS: We conducted a planned secondary data analysis of sleep outcomes in a previously conducted multicenter, double-blind, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence among community-dwelling women self-diagnosed using the 3-Incontinence Questions questionnaire. Participants (N=645) were assigned randomly to 4-8 mg antimuscarinic therapy daily or placebo. At baseline and 12 weeks, participants completed a validated voiding diary to evaluate incontinence and voiding symptoms, the Pittsburgh Sleep Quality Index to evaluate sleep quality, and the Epworth Sleepiness Scale to evaluate daytime sleepiness. RESULTS: Mean (SD) age was 56 (±14) years, 68{\%} were white, and 57{\%} had poor sleep quality (Pittsburgh Sleep Quality Index score greater than 5). Mean frequency of any urinary incontinence and UUI was 4.6 and 3.9 episodes/d, respectively. After 12 weeks, women randomized to the antimuscarinic group reported greater decrease compared with the placebo group in UUI frequency (0.9 episodes/d; P<.001) and diurnal and nocturnal voiding frequency (P<.05). As compared with the placebo group, women in the antimuscarinic group also reported greater improvement in sleep quality (total Pittsburgh Sleep Quality Index score 0.48; P=.02) with greater improvement in sleep duration and sleep efficiency subscales (P<.05). The intervention did not affect daytime sleepiness. CONCLUSION: Pharmacologic treatment of UUI is associated with decreased incontinence frequency and nocturia and improvement in overall sleep quality, sleep duration, and sleep efficiency. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00862745.",
author = "Warsi, {Qurratul A.} and Huang, {Alison J.} and Rachel Hess and Arya, {Lily A.} and Richter, {Holly E.} and Bradley, {Catherine S.} and Rogers, {Rebecca G.} and Myers, {Deborah L.} and Johnson, {Karen C.} and Winkelman, {William D.} and Gregory, {William (Tom)} and Kraus, {Stephen R.} and Michael Schembri and Brown, {Jeanette S.} and Stone, {Katie L.} and Subak, {Leslee L.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/AOG.0000000000002443",
language = "English (US)",
volume = "131",
pages = "204--211",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Association of pharmacologic treatment of urgency urinary incontinence with sleep quality and daytime sleepiness

AU - Warsi, Qurratul A.

AU - Huang, Alison J.

AU - Hess, Rachel

AU - Arya, Lily A.

AU - Richter, Holly E.

AU - Bradley, Catherine S.

AU - Rogers, Rebecca G.

AU - Myers, Deborah L.

AU - Johnson, Karen C.

AU - Winkelman, William D.

AU - Gregory, William (Tom)

AU - Kraus, Stephen R.

AU - Schembri, Michael

AU - Brown, Jeanette S.

AU - Stone, Katie L.

AU - Subak, Leslee L.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - OBJECTIVE: To evaluate the association between pharmacologic therapy for urgency urinary incontinence (UUI) and sleep quality. METHODS: We conducted a planned secondary data analysis of sleep outcomes in a previously conducted multicenter, double-blind, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence among community-dwelling women self-diagnosed using the 3-Incontinence Questions questionnaire. Participants (N=645) were assigned randomly to 4-8 mg antimuscarinic therapy daily or placebo. At baseline and 12 weeks, participants completed a validated voiding diary to evaluate incontinence and voiding symptoms, the Pittsburgh Sleep Quality Index to evaluate sleep quality, and the Epworth Sleepiness Scale to evaluate daytime sleepiness. RESULTS: Mean (SD) age was 56 (±14) years, 68% were white, and 57% had poor sleep quality (Pittsburgh Sleep Quality Index score greater than 5). Mean frequency of any urinary incontinence and UUI was 4.6 and 3.9 episodes/d, respectively. After 12 weeks, women randomized to the antimuscarinic group reported greater decrease compared with the placebo group in UUI frequency (0.9 episodes/d; P<.001) and diurnal and nocturnal voiding frequency (P<.05). As compared with the placebo group, women in the antimuscarinic group also reported greater improvement in sleep quality (total Pittsburgh Sleep Quality Index score 0.48; P=.02) with greater improvement in sleep duration and sleep efficiency subscales (P<.05). The intervention did not affect daytime sleepiness. CONCLUSION: Pharmacologic treatment of UUI is associated with decreased incontinence frequency and nocturia and improvement in overall sleep quality, sleep duration, and sleep efficiency. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00862745.

AB - OBJECTIVE: To evaluate the association between pharmacologic therapy for urgency urinary incontinence (UUI) and sleep quality. METHODS: We conducted a planned secondary data analysis of sleep outcomes in a previously conducted multicenter, double-blind, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence among community-dwelling women self-diagnosed using the 3-Incontinence Questions questionnaire. Participants (N=645) were assigned randomly to 4-8 mg antimuscarinic therapy daily or placebo. At baseline and 12 weeks, participants completed a validated voiding diary to evaluate incontinence and voiding symptoms, the Pittsburgh Sleep Quality Index to evaluate sleep quality, and the Epworth Sleepiness Scale to evaluate daytime sleepiness. RESULTS: Mean (SD) age was 56 (±14) years, 68% were white, and 57% had poor sleep quality (Pittsburgh Sleep Quality Index score greater than 5). Mean frequency of any urinary incontinence and UUI was 4.6 and 3.9 episodes/d, respectively. After 12 weeks, women randomized to the antimuscarinic group reported greater decrease compared with the placebo group in UUI frequency (0.9 episodes/d; P<.001) and diurnal and nocturnal voiding frequency (P<.05). As compared with the placebo group, women in the antimuscarinic group also reported greater improvement in sleep quality (total Pittsburgh Sleep Quality Index score 0.48; P=.02) with greater improvement in sleep duration and sleep efficiency subscales (P<.05). The intervention did not affect daytime sleepiness. CONCLUSION: Pharmacologic treatment of UUI is associated with decreased incontinence frequency and nocturia and improvement in overall sleep quality, sleep duration, and sleep efficiency. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT00862745.

UR - http://www.scopus.com/inward/record.url?scp=85048537166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048537166&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000002443

DO - 10.1097/AOG.0000000000002443

M3 - Article

C2 - 29324595

AN - SCOPUS:85048537166

VL - 131

SP - 204

EP - 211

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -